Qubigen Signs Agreement with SyzOnc to Apply AI-Driven Drug Development to Promising Oncology Targets
- David Brooks
- Sep 15
- 2 min read
Updated: Sep 22
Qubigen is pleased to announce the signing of an agreement with SyzOnc, an oncology-focused biotech company advancing novel approaches to cancer treatment. SyzOnc is grounded in world-class oncology and machine learning research from the University of Pennsylvania and the Broad Institute of Harvard and MIT, bringing cutting-edge expertise to our collaboration. The partnership marks the beginning of a focused collaboration in small molecule development, leveraging Qubigen’s AI-driven design capabilities to accelerate therapeutic development across novel targets.
SyzOnc: Tackling hard-to-treat solid tumors with targeted small-molecule therapies
SyzOnc is developing systems-level cancer therapeutics, focusing on systems level modulators of the tumor microenvironment, a critical but often overlooked aspect of solid tumor therapeutic resistance. SyzOnc identified novel biological targets and prioritized small-molecule starting points using their proprietary platform to map, model, and modulate key signaling nodes within cancer cell-matrix-immune interactions.
Qubigen’s agreement with SyzOnc covers candidate development for a novel oncogenic target protein. Qubigen will conduct computational modelling of the target protein, followed by virtual screening to identify additional potential binders, then AI-driven compound optimization to generate promising inhibitors for early experimental validation.
The project will utilize Qubigen’s provisioned Data Portal and secure Federated AI processes to ensure full data privacy and IP control for SyzOnc throughout the engagement.
A Shared Vision for Transformative Oncology Therapeutics
This collaboration reflects a shared commitment between Qubigen and SyzOnc to advance precision oncology through data-driven, iterative development cycles. By combining SyzOnc’s disease biology expertise with Qubigen’s AI infrastructure and candidate design pipelines, the partnership aims to deliver faster, more cost-effective paths to first-in-class and/or best-in-class candidates.
We are excited to support SyzOnc in pushing the boundaries of innovation in oncology drug development.
Qubigen - accelerate drug design without exposing secrets
Whether you're advancing active programs, reviving dormant data, or starting from scratch, Qubigen’s secure AI platform and virtual screening capabilities can help you identify, optimize, and accelerate the path to promising lead drug candidates. Get in touch to explore how we can support your next development.
